Samra Turajlic, MBBS, PhD, on Understanding Metastatic Disease in Renal Cancer and Melanoma
AACR Annual Meeting 2021
Samra Turajlic, MBBS, PhD, of The Francis Crick Institute, discusses our limited understanding of metastases in terms of the timing of dissemination, the many metastatic phenotypes and varieties of seeding, as well as how the spread of cancer evades the immune system and resists treatment. Expanding this knowledge base is critical to better managing malignant disease.
The ASCO Post Staff
Charlotte E. Ariyan, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses improved outcomes with metastasectomy in the setting of checkpoint inhibitors, with the removal of residual disease and “escape” lesions. Surgical outcomes may also be better than targeted treatments, although long-term data and biomarkers are needed to confirm these findings.
The ASCO Post Staff
Jeanne Tie, MD, MBChB, of the Peter MacCallum Cancer Centre, discusses how to improve the current, somewhat imprecise, approach based on pathologic staging alone, used to select patients for adjuvant treatment. Circulating tumor DNA analysis after curative-intent treatment may detect minimal residual disease and might be used to predict recurrence and adjuvant treatment efficacy across multiple tumor types.
The ASCO Post Staff
Rita Nanda, MD, of the University of Chicago, discusses the latest data on novel treatment strategies for triple-negative breast cancer, including immune checkpoint, PARP, and ATK inhibitors; antibody-drug conjugates; and targeting the androgen receptor.
The ASCO Post Staff
Karen H. Vousden, PhD, of The Francis Crick Institute, and Matthew G. Vander Heiden, MD, PhD, of the Koch Institute for Integrative Cancer Research at MIT, discuss emerging evidence that diet may affect which nutrients are available to tumor cells, which can influence both tumor growth and response to therapy. Clinicians may be able to personalize dietary interventions to optimize patient care.
The ASCO Post Staff
Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.
